ClinicalTrials.gg
TerminatedNCT04521660Updated Oct 2, 2026

The Effect of Using Virtual Reality Glasses During Coronary Angiography

An interventional study of Virtual reality glasses in Coronary Angiography, sponsored by Saglik Bilimleri Universitesi. Terminated at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Other

How we know

Why this study was terminated
The study was terminated prematurely due to the primary investigator's withdrawal from the graduate program, leaving the protocol incomplete."
Updated Oct 2, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Pain by Saglik Bilimleri Universitesi — 6 open to participants now, 8 under way, none of them phase 3. Pain · Saglik Bilimleri Universitesi.

Enrollment
2nd of 32
128 · median 73
Started
2020
with 5 others
No phase
31 of 33
5 open now
Registered
6th of 33
by date

Among the 33 studies in Pain by Saglik Bilimleri Universitesi, this one is the 2nd largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2020, is one of 31 with no phase, and was the 6th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 33 studies in Pain by Saglik Bilimleri Universitesi are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Pain by Saglik Bilimleri Universitesi, or all of them as a file.
02

Study summary

Coronary angiography (CAG) is a diagnostic method used as the gold standard in the diagnosis of coronary artery disease (CAD), which is increasingly prevalent in developed and developing countries and is one of the leading causes of morbidity and mortality in the world. Although coronary angiography is one of the best diagnostic methods of CAD, it can cause psychological problems such as stress, fear, anxiety in patients; It also causes physical problems such as bleeding, hematom and pain. Pharmacological and non-pharmacological methods are used by nurses to solve problems of patients, to ensure their relaxation and to improve their quality of life. With the development of technology, virtual reality (VR) glasses have been used to have fun at first, and later to provide pain management and to solve anxiety problems. VR glasses are an advanced technology that allows the patient to move into a virtual world and focus his attention on other thoughts, giving less attention to pain and anxiety. During literature search, no studies were found about the effect of using SG glasses on pain and anxiety during CAG. This research will be conducted to determine the effect of VR glasses used during CAG on pain, anxiety and hemodynamic parameters of patients who will experience coronary angiography for the first time.

Read the detailed description

Although coronary angiography is widely used in the diagnosis and evaluation of CAD and heart valve diseases, it causes patients to experience intense stress, anxiety, pain and even fear of death. The main purpose of nurses before an interventional procedure is to increase the physiological and mental well-being of the patient and to help them adapt to the procedure. Various pharmacological and non-pharmacological methods are used to manage the psychological and physical problems of patients undergoing coronary angiography. Distraction is one of the non-pharmacological interventions commonly used during medical procedures. Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is thought to be more effective than traditional methods. Virtual reality is a computer-generated environment in which three-dimensional interaction is possible. It projects a wide field of view in front of the user's eye through advanced head-worn screens (glasses). It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety.

This study is a randomized controlled study to determine the effectiveness of virtual reality glasses on pain, anxiety and hemodynamic parameters during coronary angiography.The universe of the study will be the individuals who will have a coronary angiography in the Angiography Laboratory of the Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital. On the other hand, the sample of the study will consist of patients who meet the inclusion criteria within the time the study is planned. Power analysis was performed using the G * Power (v3.1.7) program to determine the number of samples. It was decided that there should be at least 64 people in the groups. Participants in the study will be randomly divided into two groups as intervention and control groups. Before the procedure, patients will be informed about the purpose of the study, and written and verbal informed consent will be obtained from the patients. Patients in both groups will be asked to fill in the Personal Information Form before the procedure, and their pain levels will be evaluated with the Visual Analogue Scale (VAS), and their anxiety levels will be evaluated with the State-Trait Anxiety Inventory I (STAI-I). Immediately after the procedure, the pain levels of the patients with VAS and their anxiety levels will be evaluated with STAI-I. Virtual reality glasses will be worn on the intervention group just before the procedure starts and patients will continue to wear VR glasses until the procedure is completed. In patients selected as the control group, the same evaluations will be made at the same time interval. SPSS 22.0 (Statistical Package of Social Sciences) package program will be used for statistical analysis.

03

Conditions studied

  • Coronary Angiography

Keywords

  • virtual reality
  • pain
  • anxiety
  • hemodynamic parameters
  • angiography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being 18 years or older
  • To experience coronary angiography for the first time
  • Not having for coronary angiography
  • Not having visual and hearing impairment
  • To be orientation to place, time and person
  • Not having mental deficiency
  • Not being addicted to alcohol and drugs
  • Not being diagnosed with a psychiatric illness
  • Having agreed to participate in research

Exclusion criteria

Exclusion Criteria:

  • Having undergone a treatment procedure (stent, balloon, etc.) during coronary angiography
  • Having had a radial coronary angiography
  • Not wanting to participate in the study
  • Have used any painkillers at least 5 hours before coronary angiography
  • Making coronary angiography decision under emergency conditions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Intervention group

    Patients in the intervention group will wear virtual reality glasses during coronary angiography.

    Device: Virtual reality glasses

  • No intervention
    Control group

    Patients in the control group will not wear virtual reality glasses. They will be given standard care and treatment during the procedure.

Interventions

  • DeviceVirtual reality glasses

    Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.

06

What researchers measure

Primary outcomes

  1. Change on pain intensity as measured by Visual Analog Scale

    The average score change on pain intensity as measured by Visual Analog Scale. This scale is an unidimensional measure commonly used to measure pain intensity. The scale is a measuring tool with length of 0-10 cm. High scores on the scale indicate that pain intensity is high.

    Time frame: 'just before procedure and 30 minutes after procedure

Secondary outcomes

  1. Score change on anxiety level as measured by State-Trait Anxiety Inventory

    The average score change on anxiety level as measured by State-Trait Anxiety Inventory. This scale in used to measure anxiety. The scores on the scale ranges from 20 to 80. The high scores on the scale indicate that anxiety is high.

    Time frame: just before procedure and 30 minutes after procedure

07

Study locations

1 site
  • University of Sağlık Bilimleri
    Istanbul, 03445, Turkey (Türkiye)
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2020 to primary completion in Feb 2022, 14 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Sep 2021 → Feb 2022 and completion Sep 2021 → Feb 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2020
First posted
Aug 20, 2020
StartActual
Nov 20, 2020
Primary completionActual
Feb 1, 2022was Sep 2021
CompletionActual
Feb 1, 2022was Sep 2021
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated The study was terminated prematurely due to the primary investigator's withdrawal from the graduate program, leaving the protocol incomplete."
changed Oct 2, 2026
Primary completion
Sep 1, 2021→Feb 1, 2022 (actual)
Oct 2, 2026
Study completion
Sep 1, 2021→Feb 1, 2022 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Status unknown→Terminated
    Why stopped The study was terminated prematurely due to the primary investigator's withdrawal from the graduate program, leaving the protocol incomplete."
    Primary completion Sep 1, 2021→Feb 1, 2022 (now actual)
    Study completion Sep 1, 2021→Feb 1, 2022 (now actual)
    + 5 other changes: verification date, responsible party, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04521660
Responsible party
Elif Gezginci Akpinar (RN, PhD, Asst Prof, Saglik Bilimleri Universitesi) — Principal investigator
First posted
Aug 20, 2020
Start date
Nov 20, 2020
Primary completion
Feb 1, 2022
Completion
Feb 1, 2022
Last update
Oct 2, 2026

Study contacts

Rabia Ermis
study chair · Saglik Bilimleri University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion